Global mRNA Cancer Vaccines and Therapeutics Market is valued at USD 54.99 Billion in 2022 and is projected to attain a value of USD 193.14 Billion by 2030 at a Compound Annual Growth Rate (CAGR) of 17.00% during the forecast period, 2022–2028. A vaccination is a biological prescription for providing acquired immunity to a specific disease. It activates the immune system to recognize and eliminate the disease-causing bacterium as a threat. Vaccination, the most efficient means of preventing infectious diseases, is how it is administered. Cancer, infectious disorders like as acquired immunodeficiency syndrome (AIDS), and respiratory ailments are being treated with mRNA Cancer Vaccines and Therapeutics Market.
Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by the coronavirus 2 (SARSCoV2) of the severe acute respiratory syndrome. COVID-19, which was mostly unknown until the outbreak in Wuhan, China, in December 2019, has gone from a regional issue to a global pandemic in a matter of weeks. On March 11, 2020, the World Health Organization (WHO) proclaimed COVID-19 a pandemic. To cure the infection, a great deal of effort has gone into finding new medicines and vaccinations. Companies began developing medications and treatments to combat the virus after only a few weeks of investigation.
mRNA Cancer Vaccines and Therapeutics Market Size, 2022 To 2030 (USD Billion)
High Growth Prospects in Emerging Markets
Due to their large patient populations and rising disposable incomes, emerging regions such as India, China, and Southeast Asia provide attractive potential for the vaccination business. Major market companies have been enticed to invest in these economies because of their potential for growth. Various organisations and institutions, such as GAVI, are also working to improve vaccine use in impoverished countries, for example, by distributing vaccines at reasonable prices. As a result, these countries have become key growth hotspots in the vaccine market. Another emerging-market trend is the increased need for low-cost vaccinations. To expand the reach of immunization programs in these economies, companies are investing in and focusing on creating inexpensive, low-cost vaccines.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Inequitable Access to Vaccines
This is a critical commercial issue, particularly in impoverished areas where awareness programs and activities have either not permeated properly or not at all. Vaccines may also be difficult to obtain in some circumstances, such as in distant areas, due to a lack of adequate storage facilities and government backing. Other barriers to immunization include low literacy rates, a lack of health education, and a lack of financial resources.
The Global mRNA Cancer Vaccines and Therapeutics Market can be segmented by Application into Adeno Carcinomas, Mucinous Carcinomas and Adenosquamous Carcinomas. By End User into Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutes and Others. Based on Region, the mRNA Cancer Vaccines and Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the mRNA Cancer Vaccines and Therapeutics Market
Over the projection period, the North American region is expected to maintain its dominance. The expansion of this segment is due to factors such as a high level of public awareness about the existence of such services. Because of the increasing adoption of digital technology in the United States, the area now has a higher market share. Furthermore, the region's healthcare sector has been booming, which is expected to promote the adoption of mRNA Cancer Vaccines and Therapeutics enabled products during the projection period. Increased prevalence of chronic obstructive pulmonary disease (COPD) and respiratory illnesses, well-established healthcare infrastructure, and the presence of prominent market competitors in the region are some of the factors driving market expansion.
USD 18.51 Billion
Key industry contributors include Moderna Therapeutics (US), eTheRNA (Belgium), BioNTech (Germany), CureVac (Netherlands), In-Cell-Art (France), Translate Bio (US), Tiba Biotechnology (US), Argos Therapeutics (US), Sangamo Therapeutics (US), and Ethris (Germany).
mRNA Cancer Vaccines and Therapeutics Market is segmented as follows:
- Application (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas)
- End User (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutes, Others)
- Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Moderna Therapeutics (US)
- eTheRNA (Belgium)
- BioNTech (Germany)
- CureVac (Netherlands)
- In-Cell-Art (France)
- Translate Bio (US)
- Tiba Biotechnology (US)
- Argos Therapeutics (US)
- Sangamo Therapeutics (US)
- and Ethris (Germany).
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options
mRNA Cancer Vaccines and Therapeutics Market is tabulated as follows: